Penn Scientists Nearly Double Mouse Pancreatic Cancer Survival by Clearing Precancerous Lesions
Updated
Updated · SciTechDaily · May 29
Penn Scientists Nearly Double Mouse Pancreatic Cancer Survival by Clearing Precancerous Lesions
2 articles · Updated · SciTechDaily · May 29
Mouse models of pancreatic ductal adenocarcinoma lived nearly twice as long when KRAS-targeting drugs were given before tumors formed rather than after cancer appeared, according to a Science study led by University of Pennsylvania researchers.
Two experimental compounds from Revolution Medicines cut microscopic PanIN precancerous lesions within 10 days; with longer treatment, tumor growth slowed and one drug, RMC-7977, tripled median overall survival versus no treatment.
More than 90% of pancreatic cancers involve KRAS mutations, and nearly all PanINs carry them, making the lesions a potential interception target even though they are too small to detect on scans.
Penn researchers now plan to push the approach toward clinical trials in high-risk patients already monitored for pancreatic cysts, with possible future use in people carrying BRCA1, BRCA2, PALB2 or other strong risk factors.
Could a new 'interception' pill make one of the deadliest cancers preventable in high-risk people for the first time?
A pill to prevent cancer is a breakthrough, but could long-term use create even more drug-resistant super-cancers?
A Paradigm Shift in Pancreatic Cancer: Early KRAS Inhibition Dramatically Improves Survival
Overview
A major breakthrough reported by Penn Medicine in March 2026 marks a new era in pancreatic cancer prevention. Researchers used experimental KRAS inhibitors to eliminate precancerous lesions, called PanINs, in mouse models. Since these lesions often carry KRAS mutations that drive pancreatic ductal adenocarcinoma (PDAC), targeting them early offers a proactive way to stop cancer before it starts. This approach shifts the focus from treating established cancer to intercepting the disease at its earliest stage, opening the door to longer survival and a new paradigm in cancer care.